Cargando…
P827: EFFICACY AND SAFETY OF ROMIPLOSTIM ADDED TO IMMUNOSUPPRESSIVE THERAPY AS A FIRST-LINE TREATMENT IN PATIENTS WITH APLASTIC ANEMIA: A PHASE 2/3 CLINICAL TRIAL
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428953/ http://dx.doi.org/10.1097/01.HS9.0000846192.06541.42 |
| _version_ | 1784779280750739456 |
|---|---|
| author | Yamazaki, H. Lee, J. W. Jang, J. H. Sawa, M. Kizaki, M. Tomiyama, Y. Nagafuji, K. Usuki, K. Gau, J.-P. Morita, Y. Tang, J.-L. Chang, H. Noshiro, M. Matsuda, A. Ozawa, K. Mitani, K. Kanda, Y. Nakao, S. |
| author_facet | Yamazaki, H. Lee, J. W. Jang, J. H. Sawa, M. Kizaki, M. Tomiyama, Y. Nagafuji, K. Usuki, K. Gau, J.-P. Morita, Y. Tang, J.-L. Chang, H. Noshiro, M. Matsuda, A. Ozawa, K. Mitani, K. Kanda, Y. Nakao, S. |
| author_sort | Yamazaki, H. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9428953 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94289532022-08-31 P827: EFFICACY AND SAFETY OF ROMIPLOSTIM ADDED TO IMMUNOSUPPRESSIVE THERAPY AS A FIRST-LINE TREATMENT IN PATIENTS WITH APLASTIC ANEMIA: A PHASE 2/3 CLINICAL TRIAL Yamazaki, H. Lee, J. W. Jang, J. H. Sawa, M. Kizaki, M. Tomiyama, Y. Nagafuji, K. Usuki, K. Gau, J.-P. Morita, Y. Tang, J.-L. Chang, H. Noshiro, M. Matsuda, A. Ozawa, K. Mitani, K. Kanda, Y. Nakao, S. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9428953/ http://dx.doi.org/10.1097/01.HS9.0000846192.06541.42 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Yamazaki, H. Lee, J. W. Jang, J. H. Sawa, M. Kizaki, M. Tomiyama, Y. Nagafuji, K. Usuki, K. Gau, J.-P. Morita, Y. Tang, J.-L. Chang, H. Noshiro, M. Matsuda, A. Ozawa, K. Mitani, K. Kanda, Y. Nakao, S. P827: EFFICACY AND SAFETY OF ROMIPLOSTIM ADDED TO IMMUNOSUPPRESSIVE THERAPY AS A FIRST-LINE TREATMENT IN PATIENTS WITH APLASTIC ANEMIA: A PHASE 2/3 CLINICAL TRIAL |
| title | P827: EFFICACY AND SAFETY OF ROMIPLOSTIM ADDED TO IMMUNOSUPPRESSIVE THERAPY AS A FIRST-LINE TREATMENT IN PATIENTS WITH APLASTIC ANEMIA: A PHASE 2/3 CLINICAL TRIAL |
| title_full | P827: EFFICACY AND SAFETY OF ROMIPLOSTIM ADDED TO IMMUNOSUPPRESSIVE THERAPY AS A FIRST-LINE TREATMENT IN PATIENTS WITH APLASTIC ANEMIA: A PHASE 2/3 CLINICAL TRIAL |
| title_fullStr | P827: EFFICACY AND SAFETY OF ROMIPLOSTIM ADDED TO IMMUNOSUPPRESSIVE THERAPY AS A FIRST-LINE TREATMENT IN PATIENTS WITH APLASTIC ANEMIA: A PHASE 2/3 CLINICAL TRIAL |
| title_full_unstemmed | P827: EFFICACY AND SAFETY OF ROMIPLOSTIM ADDED TO IMMUNOSUPPRESSIVE THERAPY AS A FIRST-LINE TREATMENT IN PATIENTS WITH APLASTIC ANEMIA: A PHASE 2/3 CLINICAL TRIAL |
| title_short | P827: EFFICACY AND SAFETY OF ROMIPLOSTIM ADDED TO IMMUNOSUPPRESSIVE THERAPY AS A FIRST-LINE TREATMENT IN PATIENTS WITH APLASTIC ANEMIA: A PHASE 2/3 CLINICAL TRIAL |
| title_sort | p827: efficacy and safety of romiplostim added to immunosuppressive therapy as a first-line treatment in patients with aplastic anemia: a phase 2/3 clinical trial |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428953/ http://dx.doi.org/10.1097/01.HS9.0000846192.06541.42 |
| work_keys_str_mv | AT yamazakih p827efficacyandsafetyofromiplostimaddedtoimmunosuppressivetherapyasafirstlinetreatmentinpatientswithaplasticanemiaaphase23clinicaltrial AT leejw p827efficacyandsafetyofromiplostimaddedtoimmunosuppressivetherapyasafirstlinetreatmentinpatientswithaplasticanemiaaphase23clinicaltrial AT jangjh p827efficacyandsafetyofromiplostimaddedtoimmunosuppressivetherapyasafirstlinetreatmentinpatientswithaplasticanemiaaphase23clinicaltrial AT sawam p827efficacyandsafetyofromiplostimaddedtoimmunosuppressivetherapyasafirstlinetreatmentinpatientswithaplasticanemiaaphase23clinicaltrial AT kizakim p827efficacyandsafetyofromiplostimaddedtoimmunosuppressivetherapyasafirstlinetreatmentinpatientswithaplasticanemiaaphase23clinicaltrial AT tomiyamay p827efficacyandsafetyofromiplostimaddedtoimmunosuppressivetherapyasafirstlinetreatmentinpatientswithaplasticanemiaaphase23clinicaltrial AT nagafujik p827efficacyandsafetyofromiplostimaddedtoimmunosuppressivetherapyasafirstlinetreatmentinpatientswithaplasticanemiaaphase23clinicaltrial AT usukik p827efficacyandsafetyofromiplostimaddedtoimmunosuppressivetherapyasafirstlinetreatmentinpatientswithaplasticanemiaaphase23clinicaltrial AT gaujp p827efficacyandsafetyofromiplostimaddedtoimmunosuppressivetherapyasafirstlinetreatmentinpatientswithaplasticanemiaaphase23clinicaltrial AT moritay p827efficacyandsafetyofromiplostimaddedtoimmunosuppressivetherapyasafirstlinetreatmentinpatientswithaplasticanemiaaphase23clinicaltrial AT tangjl p827efficacyandsafetyofromiplostimaddedtoimmunosuppressivetherapyasafirstlinetreatmentinpatientswithaplasticanemiaaphase23clinicaltrial AT changh p827efficacyandsafetyofromiplostimaddedtoimmunosuppressivetherapyasafirstlinetreatmentinpatientswithaplasticanemiaaphase23clinicaltrial AT noshirom p827efficacyandsafetyofromiplostimaddedtoimmunosuppressivetherapyasafirstlinetreatmentinpatientswithaplasticanemiaaphase23clinicaltrial AT matsudaa p827efficacyandsafetyofromiplostimaddedtoimmunosuppressivetherapyasafirstlinetreatmentinpatientswithaplasticanemiaaphase23clinicaltrial AT ozawak p827efficacyandsafetyofromiplostimaddedtoimmunosuppressivetherapyasafirstlinetreatmentinpatientswithaplasticanemiaaphase23clinicaltrial AT mitanik p827efficacyandsafetyofromiplostimaddedtoimmunosuppressivetherapyasafirstlinetreatmentinpatientswithaplasticanemiaaphase23clinicaltrial AT kanday p827efficacyandsafetyofromiplostimaddedtoimmunosuppressivetherapyasafirstlinetreatmentinpatientswithaplasticanemiaaphase23clinicaltrial AT nakaos p827efficacyandsafetyofromiplostimaddedtoimmunosuppressivetherapyasafirstlinetreatmentinpatientswithaplasticanemiaaphase23clinicaltrial |